These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3376747)

  • 1. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
    Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
    Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
    Bass B; Weinshenker B; Rice GP; Noseworthy JH; Cameron MG; Hader W; Bouchard S; Ebers GC
    Can J Neurol Sci; 1988 Feb; 15(1):15-9. PubMed ID: 3345456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
    Stien R; Nordal HJ; Oftedal SI; Slettebø M
    Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
    Medici M; Pebet M; Ciblis D
    Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tizanidine in the treatment of spasticity.
    Newman PM; Nogues M; Newman PK; Weightman D; Hudgson P
    Eur J Clin Pharmacol; 1982; 23(1):31-5. PubMed ID: 6751834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of spasticity with tizanidine in multiple sclerosis.
    Lapierre Y; Bouchard S; Tansey C; Gendron D; Barkas WJ; Francis GS
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):513-7. PubMed ID: 3676923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis.
    Rice GP
    Can J Neurol Sci; 1989 Nov; 16(4):451. PubMed ID: 2804809
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
    Vakhapova V; Auriel E; Karni A
    Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A benefit-risk assessment of baclofen in severe spinal spasticity.
    Dario A; Tomei G
    Drug Saf; 2004; 27(11):799-818. PubMed ID: 15350152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
    Rushton DN; Lloyd AC; Anderson PM
    Pharmacoeconomics; 2002; 20(12):827-37. PubMed ID: 12236804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of baclofen in treatment of spasticity in multiple sclerosis.
    Sawa GM; Paty DW
    Can J Neurol Sci; 1979 Aug; 6(3):351-4. PubMed ID: 385132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis.
    Fu X; Wang Y; Wang C; Wu H; Li J; Li M; Ma Q; Yang W
    Clin Rehabil; 2018 Jun; 32(6):713-721. PubMed ID: 29582713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.